|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
2
|
Chen YC, Malfertheiner P, Yu HT, Kuo CL,
Chang YY, Meng FT, Wu YX, Hsiao JL, Chen MJ, Lin KP, et al: Global
prevalence of helicobacter pylori infection and incidence of
gastric cancer between 1980 and 2022. Gastroenterology.
166:605–619. 2024. View Article : Google Scholar
|
|
3
|
Onoyama T, Ishikawa S and Isomoto H:
Gastric cancer and genomics: Review of literature. J Gastroenterol.
57:505–516. 2022. View Article : Google Scholar
|
|
4
|
Qiu H, Cao S and Xu R: Cancer incidence,
mortality, and burden in China: A time-trend analysis and
comparison with the United States and United Kingdom based on the
global epidemiological data released in 2020. Cancer Commun (Lond).
41:1037–1048. 2021. View Article : Google Scholar
|
|
5
|
Guan WL, He Y and Xu RH: Gastric cancer
treatment: Recent progress and future perspectives. J Hematol
Oncol. 16:572023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pasquale EB: Eph receptors and ephrins in
cancer: Bidirectional signalling and beyond. Nat Rev Cancer.
10:165–180. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Iida H, Honda M, Kawai HF, Yamashita T,
Shirota Y, Wang BC, Miao H and Kaneko S: Ephrin-A1 expression
contributes to the malignant characteristics of {alpha}-fetoprotein
producing hepatocellular carcinoma. Gut. 54:843–851. 2005.
View Article : Google Scholar
|
|
8
|
Nakada M, Drake KL, Nakada S, Niska JA and
Berens ME: Ephrin-B3 ligand promotes glioma invasion through
activation of Rac1. Cancer Res. 66:8492–8500. 2006. View Article : Google Scholar
|
|
9
|
Hirai H, Maru Y, Hagiwara K, Nishida J and
Takaku F: A novel putative tyrosine kinase receptor encoded by the
eph gene. Science. 238:1717–1720. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Piffko A, Uhl C, Vajkoczy P, Czabanka M
and Broggini T: EphrinB2-EphB4 signaling in neurooncological
disease. Int J Mol Sci. 23:16792022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rutkowski R, Mertens-Walker I, Lisle JE,
Herington AC and Stephenson SA: Evidence for a dual function of
EphB4 as tumor promoter and suppressor regulated by the absence or
presence of the ephrin-B2 ligand. Int J Cancer. 131:E614–E624.
2012. View Article : Google Scholar
|
|
12
|
Piffko A, Broggini T, Harms C, Adams RH,
Vajkoczy P and Czabanka M: Ligand-dependent and ligand-independent
effects of Ephrin-B2-EphB4 signaling in melanoma metastatic spine
disease. Int J Mol Sci. 22:80282021. View Article : Google Scholar
|
|
13
|
Dai B, Shi X, Ma N, Ma W, Zhang Y, Yang T,
Zhang J and He L: HMQ-T-B10 induces human liver cell apoptosis by
competitively targeting EphrinB2 and regulating its pathway. J Cell
Mol Med. 22:5231–5243. 2018. View Article : Google Scholar
|
|
14
|
Zhong S, Pei D, Shi L, Cui Y and Hong Z:
Ephrin-B2 inhibits Aβ25-35-induced apoptosis by alleviating
endoplasmic reticulum stress and promoting autophagy in HT22 cells.
Neurosci Lett. 704:50–56. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Alam SK, Yadav VK, Bajaj S, Datta A, Dutta
SK, Bhattacharyya M, Bhattacharya S, Debnath S, Roy S, Boardman LA,
et al: DNA damage-induced ephrin-B2 reverse signaling promotes
chemoresistance and drives EMT in colorectal carcinoma harboring
mutant p53. Cell Death Differ. 23:707–722. 2016. View Article : Google Scholar :
|
|
16
|
Zhu F, Dai SN, Xu DL, Hou CQ, Liu TT, Chen
QY, Wu JL and Miao Y: EFNB2 facilitates cell proliferation,
migration, and invasion in pancreatic ductal adenocarcinoma via the
p53/p21 pathway and EMT. Biomed Pharmacother. 125:1099722020.
View Article : Google Scholar
|
|
17
|
Magic Z, Sandström J and Perez-Tenorio G:
Ephrin-B2 inhibits cell proliferation and motility in vitro and
predicts longer metastasis-free survival in breast cancer. Int J
Oncol. 55:1275–1286. 2019.
|
|
18
|
Zhang Y, Zhang R, Ding X and Ai K: EFNB2
acts as the target of miR-557 to facilitate cell proliferation,
migration and invasion in pancreatic ductal adenocarcinoma by
bioinformatics analysis and verification. Am J Transl Res.
10:3514–3528. 2018.
|
|
19
|
Akhavanfar R, Shafagh SG, Mohammadpour B,
Farahmand Y, Lotfalizadeh MH, Kookli K, Adili A, Siri G and Eshagh
Hosseini SM: A comprehensive insight into the correlation between
ncRNAs and the Wnt/β-catenin signalling pathway in gastric cancer
pathogenesis. Cell Commun Signal. 21:1662023. View Article : Google Scholar
|
|
20
|
Clevers H: Wnt/beta-catenin signaling in
development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mirabelli CK, Nusse R, Tuveson DA and
Williams BO: Perspectives on the role of Wnt biology in cancer. Sci
Signal. 12:eaay44942019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lien WH and Fuchs E: Wnt some lose some:
Transcriptional governance of stem cells by Wnt/β-catenin
signaling. Genes Dev. 28:1517–1532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar
|
|
24
|
Vasaikar SV, Straub P, Wang J and Zhang B:
LinkedOmics: Analyzing multi-omics data within and across 32 cancer
types. Nucleic Acids Res. 46:D956–D963. 2018. View Article : Google Scholar
|
|
25
|
Győrffy B: Survival analysis across the
entire transcriptome identifies biomarkers with the highest
prognostic power in breast cancer. Comput Struct Biotechnol J.
19:4101–4109. 2021. View Article : Google Scholar
|
|
26
|
Li T, Fan J, Wang B, Traugh N, Chen Q, Liu
JS, Li B and Liu XS: TIMER: A web server for comprehensive analysis
of tumor-infiltrating immune cells. Cancer Res. 77:e108–e110. 2017.
View Article : Google Scholar
|
|
27
|
Cristescu R, Lee J, Nebozhyn M, Kim KM,
Ting JC, Wong SS, Liu J, Yue YG, Wang J, Yu K, et al: Molecular
analysis of gastric cancer identifies subtypes associated with
distinct clinical outcomes. Nat Med. 21:449–456. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kim HK, Choi IJ, Kim CG, Kim HS, Oshima A,
Michalowski A and Green JE: A gene expression signature of acquired
chemoresistance to cisplatin and fluorouracil combination
chemotherapy in gastric cancer patients. PLoS One. 6:e166942011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ooi CH, Ivanova T, Wu J, Lee M, Tan IB,
Tao J, Ward L, Koo JH, Gopalakrishnan V, Zhu Y, et al: Oncogenic
pathway combinations predict clinical prognosis in gastric cancer.
PLoS Genet. 5:e10006762009. View Article : Google Scholar :
|
|
30
|
Förster S, Gretschel S, Jöns T, Yashiro M
and Kemmner W: THBS4, a novel stromal molecule of diffuse-type
gastric adenocarcinomas, identified by transcriptome-wide
expression profiling. Mod Pathol. 24:1390–1403. 2011. View Article : Google Scholar
|
|
31
|
Wang G, Hu N, Yang HH, Wang L, Su H, Wang
C, Clifford R, Dawsey EM, Li JM, Ding T, et al: Comparison of
global gene expression of gastric cardia and noncardia cancers from
a high-risk population in china. PLoS One. 8:e638262013. View Article : Google Scholar
|
|
32
|
Busuttil RA, George J, Tothill RW,
Ioculano K, Kowalczyk A, Mitchell C, Lade S, Tan P, Haviv I and
Boussioutas A: A signature predicting poor prognosis in gastric and
ovarian cancer represents a coordinated macrophage and stromal
response. Clin Cancer Res. 20:2761–2772. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cheng L, Yang S, Yang Y, Zhang W, Xiao H,
Gao H, Deng X and Zhang Q: Global gene expression and functional
network analysis of gastric cancer identify extended pathway maps
and GPRC5A as a potential biomarker. Cancer Lett. 326:105–113.
2012. View Article : Google Scholar
|
|
34
|
Lou S, Zhang J, Yin X, Zhang Y, Fang T,
Wang Y and Xue Y: Comprehensive characterization of tumor purity
and its clinical implications in gastric cancer. Front Cell Dev
Biol. 9:7825292022. View Article : Google Scholar :
|
|
35
|
Fang C, Wang W, Deng JY, Sun Z, Seeruttun
SR, Wang ZN, Xu HM, Liang H and Zhou ZW: Proposal and validation of
a modified staging system to improve the prognosis predictive
performance of the 8th AJCC/UICC pTNM staging system for gastric
adenocarcinoma: A multicenter study with external validation.
Cancer Commun (Lond). 38:672018.PubMed/NCBI
|
|
36
|
Liu Q, Li Y, Niu Z, Zong Y, Wang M, Yao L,
Lu Z, Liao Q and Zhao Y: Atorvastatin (Lipitor) attenuates the
effects of aspirin on pancreatic cancerogenesis and the
chemotherapeutic efficacy of gemcitabine on pancreatic cancer by
promoting M2 polarized tumor associated macrophages. J Exp Clin
Cancer Res. 35:332016. View Article : Google Scholar
|
|
37
|
Shen J, Cao B, Wang Y, Ma C, Zeng Z, Liu
L, Li X, Tao D, Gong J and Xie D: Hippo component YAP promotes
focal adhesion and tumour aggressiveness via transcriptionally
activating THBS1/FAK signalling in breast cancer. J Exp Clin Cancer
Res. 37:1752018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang Y, Liu Q, Liu J and Liao Q:
Upregulated CD58 is associated with clinicopathological
characteristics and poor prognosis of patients with pancreatic
ductal adenocarcinoma. Cancer Cell Int. 21:3272021. View Article : Google Scholar :
|
|
39
|
Zhang Y, Liu Q, Yang S and Liao Q:
Knockdown of LRRN1 inhibits malignant phenotypes through the
regulation of HIF-1α/notch pathway in pancreatic ductal
adenocarcinoma. Mol Ther Oncolytics. 23:51–64. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang Y, Zhang R, Luo G and Ai K: Long
noncoding RNA SNHG1 promotes cell proliferation through PI3K/AKT
signaling pathway in pancreatic ductal adenocarcinoma. J Cancer.
9:2713–2722. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Han R, Yang J, Zhu Y and Gan R: Wnt
signaling in gastric cancer: Current progress and future prospects.
Front Oncol. 14:14105132024. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Oweida A, Bhatia S, Hirsch K, Calame D,
Griego A, Keysar S, Pitts T, Sharma J, Eckhardt G, Jimeno A, et al:
Ephrin-B2 overexpression predicts for poor prognosis and response
to therapy in solid tumors. Mol Carcinog. 56:1189–1196. 2017.
View Article : Google Scholar
|
|
43
|
Ni Q, Chen P, Zhu B, Li J, Xie D and Ma X:
Expression levels of EPHB4, EFNB2 and caspase-8 are associated with
clinicopathological features and progression of esophageal squamous
cell cancer. Oncol Lett. 19:917–929. 2020.
|
|
44
|
Krusche B, Ottone C, Clements MP,
Johnstone ER, Goetsch K, Lieven H, Mota SG, Singh P, Khadayate S,
Ashraf A, et al: EphrinB2 drives perivascular invasion and
proliferation of glioblastoma stem-like cells. Elife. 5:e148452016.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Takai N, Miyazaki T, Fujisawa K, Nasu K
and Miyakawa I: Expression of receptor tyrosine kinase EphB4 and
its ligand ephrin-B2 is associated with malignant potential in
endometrial cancer. Oncol Rep. 8:567–573. 2001.
|
|
46
|
Wang L, Peng Q, Sai B, Zheng L, Xu J, Yin
N, Feng X and Xiang J: Ligand-independent EphB1 signaling mediates
TGF-β-activated CDH2 and promotes lung cancer cell invasion and
migration. J Cancer. 11:4123–4131. 2020. View Article : Google Scholar :
|
|
47
|
Peña-Blanco A and García-Sáez AJ: Bax, Bak
and beyond-mitochondrial performance in apoptosis. FEBS J.
285:416–431. 2018. View Article : Google Scholar
|
|
48
|
Tchakarska G and Sola B: The double
dealing of cyclin D1. Cell Cycle. 19:163–178. 2020. View Article : Google Scholar
|
|
49
|
Ziegler DV, Parashar K and Fajas L: Beyond
cell cycle regulation: The pleiotropic function of CDK4 in cancer.
Semin Cancer Biol. 98:51–63. 2024. View Article : Google Scholar
|
|
50
|
Koushyar S, Powell AG, Vincan E and Phesse
TJ: Targeting Wnt signaling for the treatment of gastric cancer.
Int J Mol Sci. 21:39272020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang
X, Zhou Z, Shu G and Yin G: Wnt/β-catenin signalling: Function,
biological mechanisms, and therapeutic opportunities. Signal
Transduct Target Ther. 7:32022. View Article : Google Scholar
|
|
52
|
Zhang Y and Wang X: Targeting the
Wnt/β-catenin signaling pathway in cancer. J Hematol Oncol.
13:1652020. View Article : Google Scholar
|
|
53
|
Madden SK, de Araujo AD, Gerhardt M,
Fairlie DP and Mason JM: Taking the Myc out of cancer: Toward
therapeutic strategies to directly inhibit c-Myc. Mol Cancer.
20:32021. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Xue W, Yang L, Chen C, Ashrafizadeh M,
Tian Y and Sun R: Wnt/β-catenin-driven EMT regulation in human
cancers. Cell Mol Life Sci. 81:792024. View Article : Google Scholar
|
|
55
|
Wu C, Zhuang Y, Jiang S, Liu S, Zhou J, Wu
J, Teng Y, Xia B, Wang R and Zou X: Interaction between
Wnt/β-catenin pathway and microRNAs regulates
epithelial-mesenchymal transition in gastric cancer (review). Int J
Oncol. 48:2236–2246. 2016. View Article : Google Scholar
|
